AbbVie Expects Solid FY22 As Botox, Skyrizi Power Q4 Earnings

AbbVie Inc ABBV reports Q4 adjusted EPS of $3.31, higher than $2.92 reported a year ago and beating the consensus of $3.28.

  • Overall sales increased 7.4% Y/Y (7.5% on an operational basis) to $14.89 billion, missing the consensus of $14.98 billion.
  • The immunology portfolio generated $6.75 billion in sales, +13.2% (+13.3% on an operational basis). Humira sales increased 3.5% at $5.334 billion. Skyrizi sales reached $895 million, and Rinvoq jumped 84.4% to $517 million.
  • Hematologic oncology portfolio sales were $1.87 billion, +4.6% (+4.7% on an operational basis). Imbruvica sales decreased 2.7% to $1.38 billion. Venclexta revenues were up 33% to $488 million.
  • Sales from the neuroscience portfolio reached $1.65 billion, +19%. Aesthetics portfolio sales increased 23.3% (+22.8% on an operational basis) to $1.41 billion, with $626 million in Botox sales for cosmetic uses.
  • Adjusted gross margin expanded from 81.8% to 83.6%. The adjusted operating margin also improved from 46.9% to 49.3%.
  • FY22 guidance: AbbVie expects FY22 adjusted EPS of $14.00 - $14.20, versus the consensus of $13.99.
  • Price Action: ABBV shares are up 0.49% at $137.67 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!